J Gynecol Oncol.  2013 Jan;24(1):44-51. 10.3802/jgo.2013.24.1.44.

Histologic distribution of borderline ovarian tumors worldwide: a systematic review

• Song T
• Lee YY
• Choi CH
• Kim TJ
• Lee JW
• Bae DS
• Kim BG

• KMID: 2288560
• DOI: http://doi.org/10.3802/jgo.2013.24.1.44

Abstract

OBJECTIVE
The histologic types of borderline ovarian tumors (BOTs) exhibit striking differences in clinical behavior and prognosis. Yet, there is no information available on the histologic distribution of BOTs according to geographic region. The purpose of this study was to systematically review this issue worldwide.
METHODS
A comprehensive search of the literature was conducted using electronic databases. Studies were eligible if BOTs were investigated and the histologic distribution of the data was shown. The studies were grouped by geographic region and totaled by country.
RESULTS
Of 487 potentially relevant studies, 51 met our inclusion criteria, as follows: 8 studies from North America (2 countries); 26 studies from Europe (14 countries); 7 studies from the Middle East (3 countries); and 10 studies from East Asia (5 countries). The histologic distribution of BOTs was considerably different in different parts of the world, but follows specific patterns. In general, serous-type BOTs were the predominantly identified histology in North America, the Middle East, and Europe, while mucinous-type BOTs predominated in East Asia.
CONCLUSION
Significant geographic variation is evident among BOT histology in different parts of the world. More research is needed to understand this phenomenon.

Keyword

Borderline ovarian tumor; Histology; Low malignant potential; Systematic review

MeSH Terms

Electronics
Electrons
Europe
Far East
Middle East
North America
Prognosis
Strikes, Employee

Figure

• 

  Fig. 1 Search process and eligible studies (Preferred Reporting of Systematic Reviews and Meta-Analyses [PRISMA] flow diagram).

• 

  Fig. 2 World map based on tumor histology according to geographic region (country).

Reference

1. Taylor HC Jr. Malignant and semimalignant tumors of the ovary. Surg Gynecol Obstet. 1929. 48:204–230.

2. Cadron I, Leunen K, Van Gorp T, Amant F, Neven P, Vergote I. Management of borderline ovarian neoplasms. J Clin Oncol. 2007. 25:2928–2937.

3. Koskas M, Uzan C, Gouy S, Pautier P, Lhomme C, Haie-Meder C, et al. Fertility determinants after conservative surgery for mucinous borderline tumours of the ovary (excluding peritoneal pseudomyxoma). Hum Reprod. 2011. 26:808–814.

4. Uzan C, Kane A, Rey A, Gouy S, Duvillard P, Morice P. Outcomes after conservative treatment of advanced-stage serous borderline tumors of the ovary. Ann Oncol. 2010. 21:55–60.

5. Silverberg SG, Bell DA, Kurman RJ, Seidman JD, Prat J, Ronnett BM, et al. Borderline ovarian tumors: key points and workshop summary. Hum Pathol. 2004. 35:910–917.

6. Shih KK, Zhou Q, Huh J, Morgan JC, Iasonos A, Aghajanian C, et al. Risk factors for recurrence of ovarian borderline tumors. Gynecol Oncol. 2011. 120:480–484.

7. Camatte S, Morice P, Thoury A, Fourchotte V, Pautier P, Lhomme C, et al. Impact of surgical staging in patients with macroscopic "stage I" ovarian borderline tumours: analysis of a continuous series of 101 cases. Eur J Cancer. 2004. 40:1842–1849.

8. Romagnolo C, Gadducci A, Sartori E, Zola P, Maggino T. Management of borderline ovarian tumors: results of an Italian multicenter study. Gynecol Oncol. 2006. 101:255–260.

9. Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. Surgical management of borderline ovarian tumors: The role of fertility-sparing surgery. Gynecol Oncol. 2009. 113:75–82.

10. Kokawa K, Mikami Y, Sakata H, Oki N, Tanakas T, Yamazaki M, et al. Clinical outcome and prognostic factors in borderline tumors of the ovary: results from 17 years' experience in the Kinki District of Japan (1990-2006). Eur J Gynaecol Oncol. 2009. 30:155–161.

11. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009. 151:264–269. W64

12. Huusom LD, Frederiksen K, Hogdall EV, Glud E, Christensen L, Hogdall CK, et al. Association of reproductive factors, oral contraceptive use and selected lifestyle factors with the risk of ovarian borderline tumors: a Danish case-control study. Cancer Causes Control. 2006. 17:821–829.

13. Jordan SJ, Whiteman DC, Purdie DM, Green AC, Webb PM. Does smoking increase risk of ovarian cancer? A systematic review. Gynecol Oncol. 2006. 103:1122–1129.

14. Benito V, Lubrano A, Arencibia O, Medina N, Alvarez Eva E, Andujar M, et al. Serous and mucinous borderline ovarian tumors: are there real differences between these two entities? Eur J Obstet Gynecol Reprod Biol. 2010. 153:188–192.

15. Jha P, Ranson MK, Nguyen SN, Yach D. Estimates of global and regional smoking prevalence in 1995, by age and sex. Am J Public Health. 2002. 92:1002–1006.

16. Koskas M, Uzan C, Gouy S, Pautier P, Lhomme C, Haie-Meder C, et al. Prognostic factors of a large retrospective series of mucinous borderline tumors of the ovary (excluding peritoneal pseudomyxoma). Ann Surg Oncol. 2011. 18:40–48.

17. Anfinan N, Sait K, Ghatage P, Nation J, Chu P. Ten years experience in the management of borderline ovarian tumors at Tom Baker Cancer Centre. Arch Gynecol Obstet. 2011. 284:731–735.

18. Rice LW, Lage JM, Berkowitz RS, Goodman A, Muto MG, Knapp RC, et al. Preoperative serum CA-125 levels in borderline tumors of the ovary. Gynecol Oncol. 1992. 46:226–229.

19. Morris RT, Gershenson DM, Silva EG, Follen M, Morris M, Wharton JT. Outcome and reproductive function after conservative surgery for borderline ovarian tumors. Obstet Gynecol. 2000. 95:541–547.

20. Rettenmaier MA, Lopez K, Abaid LN, Brown JV 3rd, Micha JP, Goldstein BH. Borderline ovarian tumors and extended patient follow-up: an individual institution's experience. J Surg Oncol. 2010. 101:18–21.

21. Vine MF, Ness RB, Calingaert B, Schildkraut JM, Berchuck A. Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor. Gynecol Oncol. 2001. 83:466–471.

22. Rao GG, Skinner EN, Gehrig PA, Duska LR, Miller DS, Schorge JO. Fertility-sparing surgery for ovarian low malignant potential tumors. Gynecol Oncol. 2005. 98:263–266.

23. Mink PJ, Sherman ME, Devesa SS. Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States: results from the SEER Program, 1978-1998. Cancer. 2002. 95:2380–2389.

24. Odegaard E, Staff AC, Langebrekke A, Engh V, Onsrud M. Surgery of borderline tumors of the ovary: retrospective comparison of short-term outcome after laparoscopy or laparotomy. Acta Obstet Gynecol Scand. 2007. 86:620–626.

25. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, et al. Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study. Gynecol Oncol. 2001. 83:575–585.

26. Akeson M, Zetterqvist BM, Dahllof K, Jakobsen AM, Brannstrom M, Horvath G. Population-based cohort follow-up study of all patients operated for borderline ovarian tumor in western Sweden during an 11-year period. Int J Gynecol Cancer. 2008. 18:453–459.

27. Kumpulainen S, Kuoppala T, Leminen A, Komulainen M, Puistola U, Sankila R, et al. Surgical staging, treatment, and follow-up of borderline tumors in different hospital categories: a prospective nationwide survey in Finland. Acta Obstet Gynecol Scand. 2007. 86:610–614.

28. Hannibal CG, Huusom LD, Kjaerbye-Thygesen A, Tabor A, Kjaer SK. Trends in incidence of borderline ovarian tumors in Denmark 1978-2006. Acta Obstet Gynecol Scand. 2011. 90:305–312.

29. Engelen MJ, de Bruijn HW, Hollema H, ten Hoor KA, Willemse PH, Aalders JG, et al. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors. Gynecol Oncol. 2000. 78:16–20.

30. Kolwijck E, Thomas CM, Bulten J, Massuger LF. Preoperative CA-125 levels in 123 patients with borderline ovarian tumors: a retrospective analysis and review of the literature. Int J Gynecol Cancer. 2009. 19:1335–1338.

31. Verbruggen MB, van Diest PJ, Baak JP, Broeckaert MA, Kenemans P, Verheijen RH. The prognostic and clinical value of morphometry and DNA cytometry in borderline ovarian tumors: a prospective study. Int J Gynecol Pathol. 2009. 28:35–40.

32. Donnez J, Munschke A, Berliere M, Pirard C, Jadoul P, Smets M, et al. Safety of conservative management and fertility outcome in women with borderline tumors of the ovary. Fertil Steril. 2003. 79:1216–1221.

33. Fotopoulou C, Schumacher G, Schefold JC, Denkert C, Lichtenegger W, Sehouli J. Systematic evaluation of the intraoperative tumor pattern in patients with borderline tumor of the ovary. Int J Gynecol Cancer. 2009. 19:1550–1555.

34. Ivanov S. Borderline ovarian tumors. Akush Ginekol (Sofiia). 2002. 42:23–25.

35. Makarewicz H, Emerich J, Olszewski J. Comparison of two groups of patients with serous and mucinous types of borderline ovarian tumors. Ginekol Pol. 2003. 74:24–31.

36. Bouchardy C, Fernandez S, Merglen A, Usel M, Fioretta G, Rapiti E, et al. Increased risk of second cancer among patients with ovarian borderline tumors. Gynecol Oncol. 2008. 109:210–214.

37. Levi F, La Vecchia C, Randimbison L, Te VC. Borderline ovarian tumours in Vaud, Switzerland: incidence, survival and second neoplasms. Br J Cancer. 1999. 79:4–6.

38. Fauvet R, Boccara J, Dufournet C, Poncelet C, Darai E. Laparoscopic management of borderline ovarian tumors: results of a French multicenter study. Ann Oncol. 2005. 16:403–410.

39. De Iaco P, Ferrero A, Rosati F, Melpignano M, Biglia N, Rolla M, et al. Behaviour of ovarian tumors of low malignant potential treated with conservative surgery. Eur J Surg Oncol. 2009. 35:643–648.

40. Maneo A, Vignali M, Chiari S, Colombo A, Mangioni C, Landoni F. Are borderline tumors of the ovary safely treated by laparoscopy? Gynecol Oncol. 2004. 94:387–392.

41. Palomba S, Zupi E, Russo T, Falbo A, Del Negro S, Manguso F, et al. Comparison of two fertility-sparing approaches for bilateral borderline ovarian tumours: a randomized controlled study. Hum Reprod. 2007. 22:578–585.

42. Zanetta G, Rota S, Chiari S, Bonazzi C, Bratina G, Mangioni C. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol. 2001. 19:2658–2664.

43. Cusido M, Balaguero L, Hernandez G, Falcon O, Rodriguez-Escudero FJ, Vargas JA, et al. Results of the national survey of borderline ovarian tumors in Spain. Gynecol Oncol. 2007. 104:617–622.

44. Martin Jimenez A, Miralles Pi RM, Escobedo Sanchez A, Gine Martinez L, Condom Mundo E, Balaguero Llado L. Ovarian tumors of low malignant potential (borderline): a retrospective study of 31 cases. Eur J Gynaecol Oncol. 1994. 15:300–304.

45. Liapis A, Bakalianou K, Iavazzo C, Salakos N, Paltoglou G, Kondi-Pafiti A. A retrospective analysis of borderline ovarian tumors in a Greek university hospital. Eur J Gynaecol Oncol. 2008. 29:383–385.

46. Economou A, Panagopoulos P, Koutras I, Petrakos G, Karadaglis S, Karcanis C. A retrospective study of 32 borderline ovarian tumours: the experience of a non-specialized centre. Eur J Gynaecol Oncol. 2005. 26:196–198.

47. Ayhan A, Guvendag Guven ES, Guven S, Kucukali T. Recurrence and prognostic factors in borderline ovarian tumors. Gynecol Oncol. 2005. 98:439–445.

48. Boran N, Cil AP, Tulunay G, Ozturkoglu E, Koc S, Bulbul D, et al. Fertility and recurrence results of conservative surgery for borderline ovarian tumors. Gynecol Oncol. 2005. 97:845–851.

49. Kanat-Pektas M, Ozat M, Gungor T, Sahin I, Yalcin H, Ozdal B. Complete lymph node dissection: is it essential for the treatment of borderline epithelial ovarian tumors? Arch Gynecol Obstet. 2011. 283:879–884.

50. Pirimoglu ZM, Afsin Y, Guzelmeric K, Yilmaz M, Unal O, Turan MC. Is it necessary to do retroperitoneal evaluation in borderline epithelial ovarian tumors? Arch Gynecol Obstet. 2008. 277:411–414.

51. Gotlieb WH, Chetrit A, Menczer J, Hirsh-Yechezkel G, Lubin F, Friedman E, et al. Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer. Gynecol Oncol. 2005. 97:780–783.

52. Iscovich J, Shushan A, Schenker JG, Paltiel O. The incidence of borderline ovarian tumors in Israel: a population-based study. Cancer. 1998. 82:147–151.

53. Behtash N, Modares M, Abolhasani M, Ghaemmaghami F, Mousavi M, Yarandi F, et al. Borderline ovarian tumours: clinical analysis of 38 cases. J Obstet Gynaecol. 2004. 24:157–160.

54. Li Y, Cui H, Shen DH, Zhao Y, Wei LH, Qian HN. Clinical and pathological features of borderline ovarian tumors. Zhonghua Fu Chan Ke Za Zhi. 2003. 38:81–84.

55. Ren J, Lou JY, Liu H, Wang P, Zhang JW, Yang KX, et al. Clinicopathologic features of 234 cases with borderline ovarian tumors. Zhonghua Fu Chan Ke Za Zhi. 2009. 44:116–120.

56. Zhang Z, Hong W, Li L. The clinical features and management of borderline ovarian tumors. Zhonghua Fu Chan Ke Za Zhi. 1998. 33:556–559.

57. Wong HF, Low JJ, Chua Y, Busmanis I, Tay EH, Ho TH. Ovarian tumors of borderline malignancy: a review of 247 patients from 1991 to 2004. Int J Gynecol Cancer. 2007. 17:342–349.

58. Wu TI, Lee CL, Wu MY, Hsueh S, Huang KG, Yeh CJ, et al. Prognostic factors predicting recurrence in borderline ovarian tumors. Gynecol Oncol. 2009. 114:237–241.

59. Kim JH, Kim TJ, Park YG, Lee SH, Lee CW, Song MJ, et al. Clinical analysis of intra-operative frozen section proven borderline tumors of the ovary. J Gynecol Oncol. 2009. 20:176–180.

60. Tamakoshi K, Kikkawa F, Nakashima N, Tamakoshi A, Kawai M, Furuhashi Y, et al. Clinical behavior of borderline ovarian tumors: a study of 150 cases. J Surg Oncol. 1997. 64:147–152.

61. Yokoyama Y, Moriya T, Takano T, Shoji T, Takahashi O, Nakahara K, et al. Clinical outcome and risk factors for recurrence in borderline ovarian tumours. Br J Cancer. 2006. 94:1586–1591.